Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab plus enzalutamide versus placebo plus enzalutamide in metastatic castration-resistant prostate cancer; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Xtandi (enzalutamide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-12-20